Reports
Sale
Global Proton Pump Inhibitors (PPIs) Market Size, Forecast: By Product Type: OTC Drugs, Prescription Drugs; Regional Analysis; Market Dynamics: SWOT Analysis, Porter’s Five Forces Model; Patent Analysis; Grants Analysis; Funding Analysis; Partnership and Collaborations Analysis; Supplier Landscape; 2024-2032
Global Proton Pump Inhibitors (PPIs) Market Outlook
The global proton pump inhibitors (PPIs) market size was valued at USD 3.2 billion in 2023, driven by the rising incidence of gastroesophageal reflux disease (GERD) cases across the globe. The market is expected to grow at a CAGR of 4.50% during the forecast period of 2024-2032, with the values likely to rise from USD 3.34 billion in 2024 to USD 4.76 billion by 2032.
Read more about this report - REQUEST FREE SAMPLE COPY IN PDF
Proton Pump Inhibitors (PPIs): Introduction
Proton pump inhibitors are medicines used to control the acid released through the glands in the lining of the stomach. They are used to relieve the symptoms of acid reflux or gastroesophageal reflux disease (GERD), along with treating stomach ulcers and damage to the lower esophagus caused by acid reflux. Omeprazole, Esomeprazole, and Lansoprazole are some of the most common types of proton pump inhibitors sold in the market.
Global Proton Pump Inhibitors (PPIs) Market Analysis
In the historical period, the proton pump inhibitors (PPIs) market value has observed a significant upswing owing to the high accessibility and affordability of the drugs. The market is segmented into over-the-counter drugs and prescription drugs like Rabeprazole and Pantoprazole, among others. In addition, a rise in the prevalence of gastrointestinal disorders like peptic ulcers and GERD, especially driven by lifestyle and an aging population have driven the high market demand.
With a deeper understanding of human physiology, coupled with improving research and development infrastructure, health institutions have identified the potential risks of prolonged PPI usage which include kidney damage, osteoporosis, and infections. As a result, the proton pump inhibitors (PPIs) market growth has slowed down in recent years. There is immense focus on cautious prescribing practices along with rising development of generic and novel drugs. Along with novel drug formulations, non-pharmacological treatments are also emerging in the market, which are expected to affect the market.
Read more about this report - REQUEST FREE SAMPLE COPY IN PDF
Global Proton Pump Inhibitors (PPIs) Market Segmentation
Market Breakup by Product Type
- OTC Drugs
- Omeprazole
- Lansoprazole
- Esomeprazole
- Other OTC Drugs
- Prescription Drugs
- Rabeprazole
- Dexlansoprazole
- Pantoprazole
Market Breakup by Region
- North America
- Europe
- Asia Pacific
- Latin America
- Middle East and Africa
Read more about this report - REQUEST FREE SAMPLE COPY IN PDF
Global Proton Pump Inhibitors (PPIs) Market Overview
The United States has held significant proton pump inhibitors (PPIs) market share in the historical period. The presence of key healthcare players which are continuously working to acquire smaller companies and drive innovation through improved research and development and expanding market reach is a vital factor. Moreover, the regulatory authorities like FDA closely monitor the safety profile of PPIs, their potential side effects and promoting quality distribution of the drugs.
Europe, being home to several influential healthcare and academic institutions, is contributing to fostering the proton pump inhibitors (PPIs) market demand in the region. With high prevalence of gastrointestinal diseases, especially in the geriatric population, makes the region a major market for PPIs.
The Asia Pacific region with rising development and improving healthcare infrastructure is expected to witness rapid growth in the forecast period. The region is experiencing several foreign investments from major healthcare companies, which are working on setting up research labs in the region. With such initiatives, they can leverage the area’s academic talent to develop novel drugs.
Global Proton Pump Inhibitors (PPIs) Market: Competitor Landscape
The key features of the market report include patent analysis, grants analysis, clinical trials analysis, funding and investment analysis, partnerships, and collaborations analysis by the leading key players. The major companies in the market are as follows:
- AstraZeneca
- Bayer AG
- Cadila Pharmaceuticals
- GlaxoSmithKline PLC
- Pfizer
- Eisai Pharmaceuticals
- Santarus, Inc
- Wyeth
- Janssen Pharmaceutical
- Takeda Pharmaceutical Company Limited
- Sanofi S.A.
- Teva Pharmaceuticals
- Eli Lilly
Please note that this only represents a partial list of companies, and the complete list has been provided in the report.
Key Highlights of the Report
| REPORT FEATURES | DETAILS |
| Base Year | 2023 |
| Historical Period | 2017-2023 |
| Forecast Period | 2024-2032 |
| Scope of the Report |
Historical and Forecast Trends, Industry Drivers and Constraints, Historical and Forecast Market Analysis by Segment:
|
| Breakup by Product Type |
|
| Breakup by Region |
|
| Market Dynamics |
|
| Competitive Landscape |
|
| Companies Covered |
|
*At Expert Market Research, we strive to always give you current and accurate information. The numbers depicted in the description are indicative and may differ from the actual numbers in the final EMR report.
1 Preface
1.1 Objectives of the Study
1.2 Key Assumptions
1.3 Report Coverage – Key Segmentation and Scope
1.4 Research Methodology
2 Executive Summary
3 Global Proton Pump Inhibitors Market Overview
3.1 Global Proton Pump Inhibitors Market Historical Value (2017-2023)
3.2 Global Proton Pump Inhibitors Market Forecast Value (2024-2032)
4 Global Proton Pump Inhibitors Market Landscape
4.1 Global Proton Pump Inhibitors Developers Landscape
4.1.1 Analysis by Year of Establishment
4.1.2 Analysis by Company Size
4.1.3 Analysis by Region
4.2 Global Proton Pump Inhibitors Product Landscape
4.2.1 Analysis by Product Type
4.2.2 Analysis by Type
4.2.3 Analysis by Applications
5 Global Proton Pump Inhibitors Market Dynamics
5.1 Market Drivers and Constraints
5.2 SWOT Analysis
5.3 Porter’s Five Forces Model
5.4 Key Demand Indicators
5.5 Key Price Indicators
5.6 Industry Events, Initiatives, and Trends
5.7 Value Chain Analysis
6 Global Proton Pump Inhibitors Market Segmentation
6.1 Global Proton Pump Inhibitors Market by Product Type
6.1.1 Market Overview
6.1.2 OTC Drugs
6.1.2.1 Omeprazole
6.1.2.2 Lansoprazole
6.1.2.3 Esomeprazole
6.1.2.4 Other OTC Drugs
6.1.3 Prescription Drugs
6.1.3.1 Rabeprazole
6.1.3.2 Dex lansoprazole
6.1.3.3 Pantoprazole
6.2 Global Proton Pump Inhibitors Market by Region
6.2.1 Market Overview
6.2.2 North America
6.2.3 Europe
6.2.4 Asia Pacific
6.2.5 Latin America
6.2.6 Middle East and Africa
7 North America Proton Pump Inhibitors Market
7.1 Market Share by Country
7.2 United States of America
7.3 Canada
8 Europe Proton Pump Inhibitors Market
8.1 Market Share by Country
8.2 United Kingdom
8.3 Germany
8.4 France
8.5 Italy
8.6 Others
9 Asia Pacific Proton Pump Inhibitors Market
9.1 Market Share by Country
9.2 China
9.3 Japan
9.4 India
9.5 ASEAN
9.6 Australia
9.7 Others
10 Latin America Proton Pump Inhibitors Market
10.1 Market Share by Country
10.2 Brazil
10.3 Argentina
10.4 Mexico
10.5 Others
11 Middle East and Africa Proton Pump Inhibitors Market
11.1 Market Share by Country
11.2 Saudi Arabia
11.3 United Arab Emirates
11.4 Nigeria
11.5 South Africa
11.6 Others
12 Patent Analysis
12.1 Analysis by Type of Patent
12.2 Analysis by Publication year
12.3 Analysis by Issuing Authority
12.4 Analysis by Patent Age
12.5 Analysis by CPC Analysis
12.6 Analysis by Patent Valuation
12.7 Analysis by Key Players
13 Grants Analysis
13.1 Analysis by year
13.2 Analysis by Amount Awarded
13.3 Analysis by Issuing Authority
13.4 Analysis by Grant Application
13.5 Analysis by Funding Institute
13.6 Analysis by NIH Departments
13.7 Analysis by Recipient Organization
14 Funding Analysis
14.1 Analysis by Funding Instances
14.2 Analysis by Type of Funding
14.3 Analysis by Funding Amount
14.4 Analysis by Leading Players
14.5 Analysis by Leading Investors
14.6 Analysis by Geography
15 Partnership and Collaborations Analysis
15.1 Analysis by Partnership Instances
15.2 Analysis by Type of Partnership
15.3 Analysis by Leading Players
15.4 Analysis by Geography
16 Regulatory Framework
16.1 Regulatory Overview
16.1.1 US FDA
16.1.2 EU EMA
16.1.3 INDIA CDSCO
16.1.4 JAPAN PMDA
16.1.5 Others
17 Supplier Landscape
17.1 AstraZeneca
17.1.1 Financial Analysis
17.1.2 Product Portfolio
17.1.3 Demographic Reach and Achievements
17.1.4 Mergers and Acquisition
17.1.5 Certifications
17.2 Bayer AG
17.2.1 Financial Analysis
17.2.2 Product Portfolio
17.2.3 Demographic Reach and Achievements
17.2.4 Mergers and Acquisition
17.2.5 Certifications
17.3 Cadila Pharmaceuticals
17.3.1 Financial Analysis
17.3.2 Product Portfolio
17.3.3 Demographic Reach and Achievements
17.3.4 Mergers and Acquisition
17.3.5 Certifications
17.4 GlaxoSmithKline PLC
17.4.1 Financial Analysis
17.4.2 Product Portfolio
17.4.3 Demographic Reach and Achievements
17.4.4 Mergers and Acquisition
17.4.5 Certifications
17.5 Pfizer
17.5.1 Financial Analysis
17.5.2 Product Portfolio
17.5.3 Demographic Reach and Achievements
17.5.4 Mergers and Acquisition
17.5.5 Certifications
17.6 Eisai Pharmaceuticals
17.6.1 Financial Analysis
17.6.2 Product Portfolio
17.6.3 Demographic Reach and Achievements
17.6.4 Mergers and Acquisition
17.6.5 Certifications
17.7 Santarus, Inc
17.7.1 Financial Analysis
17.7.2 Product Portfolio
17.7.3 Demographic Reach and Achievements
17.7.4 Mergers and Acquisition
17.7.5 Certifications
17.8 Wyeth
17.8.1 Financial Analysis
17.8.2 Product Portfolio
17.8.3 Demographic Reach and Achievements
17.8.4 Mergers and Acquisition
17.8.5 Certifications
17.9 Janssen Pharmaceutical
17.9.1 Financial Analysis
17.9.2 Product Portfolio
17.9.3 Demographic Reach and Achievements
17.9.4 Mergers and Acquisition
17.9.5 Certifications
17.10 Takeda Pharmaceutical Company Limited
17.10.1 Financial Analysis
17.10.2 Product Portfolio
17.10.3 Demographic Reach and Achievements
17.10.4 Mergers and Acquisition
17.10.5 Certifications
17.11 Sanofi S.A.
17.11.1 Financial Analysis
17.11.2 Product Portfolio
17.11.3 Demographic Reach and Achievements
17.11.4 Mergers and Acquisition
17.11.5 Certifications
17.12 Teva Pharmaceuticals
17.12.1 Financial Analysis
17.12.2 Product Portfolio
17.12.3 Demographic Reach and Achievements
17.12.4 Mergers and Acquisition
17.12.5 Certifications
17.13 Eli Lilly
17.13.1 Financial Analysis
17.13.2 Product Portfolio
17.13.3 Demographic Reach and Achievements
17.13.4 Mergers and Acquisition
17.13.5 Certifications
18 Global Proton Pump Inhibitors Market - Distribution Model (Additional Insight)
18.1 Overview
18.2 Potential Distributors
18.3 Key Parameters for Distribution Partner Assessment
19 Key Opinion Leaders (KOL) Insights (Additional Insight)
20 Company Competitiveness Analysis (Additional Insight)
20.1 Very Small Companies
20.2 Small Companies
20.3 Mid-Sized Companies
20.4 Large Companies
20.5 Very Large Companies
21 Payment Methods (Additional Insight)
21.1 Government Funded
21.2 Private Insurance
21.3 Out-of-Pocket
*Additional insights provided are customisable as per client requirements.
Key Questions Answered in the Report
The market attained a value of about USD 3.2 billion in 2023, driven by the rising prevalence of GERD (gastroesophageal reflux disease) across the globe.
The market is anticipated to grow at a CAGR of 4.50% during the forecast period of 2024-2032, likely to reach a market value of USD 4.76 billion by 2032.
The high market demand is driven by the rising investments and development for novel drugs for treating gastrointestinal diseases.
As per the current market trend, the Asia Pacific region is expected to witness the growth of the market, on a contrary to the historic period, wherein North America experienced rapid growth.
The market can be broadly categorised based on drug type into OTC drugs and prescription drugs. OTC drugs are further divided into omeprazole, lansoprazole, and esomeprazole, among others, while prescription drugs are sub-divided into rabeprazole, dexlansoprazole, and pantoprazole.
The major regions of the market include North America, Europe, Asia Pacific, Latin America, Middle East, and Africa. North America is currently leading the global market.
Key players involved in the market are AstraZeneca, Bayer AG, Cadila Pharmaceuticals, GlaxoSmithKline PLC, Pfizer, Eisai Pharmaceuticals, Santarus, Inc, Wyeth, Janssen Pharmaceutical, Takeda Pharmaceutical Company Limited, Sanofi S.A., Teva Pharmaceuticals and Eli Lilly.
Purchase Options 10% off
Call us
Purchase Full Report
Mini Report
$ 2969
$2699
-
Selected Sections, One User
-
Printing Not Allowed
-
Email Delivery in PDF
-
Free Limited Customisation -
Post Sales Analyst Support -
50% Discount on Next Update
Single User License
$ 5499
$4999
-
All Sections, One User
-
One Print Allowed
-
Email Delivery in PDF
-
Free Limited Customisation -
Post Sales Analyst Support -
50% Discount on Next Update
Five User License
$ 6599
$5999
-
All Sections, Five Users
-
Five Prints Allowed
-
Email Delivery in PDF
-
Free Limited Customisation
-
Post Sales Analyst Support
-
50% Discount on Next Update
Corporate License
$ 7699
$6999
-
All Sections, Unlimited Users
-
Unlimited Prints Allowed
-
Email Delivery in PDF + Excel
-
Free Limited Customisation
-
Post Sales Analyst Support
-
50% Discount on Next Update
Any Question? Speak With An Analyst
View A Sample
Did You Miss Anything, Ask Now
Why Expert Market Research?
Right People
We are technically excellent, strategic, practical, experienced and efficient; our analysts are hand-picked based on having the right attributes to work successfully and execute projects based on your expectations.
Right Methodology
We leverage our cutting-edge technology, our access to trusted databases, and our knowledge of the current models used in the market to deliver you research solutions that are tailored to your needs and put you ahead of the curve.
Right Price
We deliver in-depth and superior quality research in prices that are reasonable, unmatchable, and shows our understanding of your resource structure. We, additionally, offer attractive discounts on our upcoming reports.
Right Support
Our team of expert analysts are at your beck and call to deliver you optimum results that are customised to meet your precise needs within the specified timeframe and help you form a better understanding of the industry.
NEWSLETTER